A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Baltimore, Maryland 21231-1000, United States
Capital Federal, Buenos Aires 1431, Argentina
San Miguel de Tucumán, Tucumán Province 4000, Argentina
Halfax, Nova Scotia B3H 2Y9, Canada
Osaka-sayama-shi, Osaka 5898511, Japan
Kobe-city, Hyogo, 650-0017, Japan
Lorenskog, 1478, Norway
Gothenberg, 413 45, Sweden